Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and cetuximab in advanced or metastatic biliary tract cancer
2007-005850-22Phase 2Completed
- Sponsor
- Belgian Group of Digestive Oncology
- Start
- Jan 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cetuximab in cholangiocarcinoma (CCA), sponsored by Belgian Group of Digestive Oncology. Primary endpoint: Progression-free survival at 24 weeks. Started Jan 2008; status: completed.
02
Drugs
gemcitabinecetuximab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2007-005850-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005850-22.